Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $5.64, for a total value of $39,044,986.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Aura Biosciences Price Performance
NASDAQ:AURA traded down $0.21 during trading hours on Monday, hitting $8.19. The company’s stock had a trading volume of 332,249 shares, compared to its average volume of 349,795. The stock has a fifty day simple moving average of $6.66 and a 200-day simple moving average of $6.05. The company has a market capitalization of $525.80 million, a P/E ratio of -4.58 and a beta of 0.37. Aura Biosciences, Inc. has a twelve month low of $4.34 and a twelve month high of $9.53.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.10). On average, equities analysts predict that Aura Biosciences, Inc. will post -1.63 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
AURA has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Friday, March 27th. Wall Street Zen upgraded Aura Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, HC Wainwright lifted their target price on Aura Biosciences from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $21.50.
Get Our Latest Stock Analysis on AURA
About Aura Biosciences
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Featured Articles
- Five stocks we like better than Aura Biosciences
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
